导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 8.05% | 962/4773 |
| 近一周 | -0.51% | 1109/5465 |
| 近一月 | -3.82% | 2828/5421 |
| 近一季 | -4.23% | 1768/5231 |
| 近半年 | -2.00% | 1985/4920 |
| 近一年 | 13.92% | 857/4394 |
| 近两年 | 80.53% | 841/2954 |
| 近三年 | 49.65% | 561/2253 |
| 成立以来 | 40.90% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.15% 798/4961 |
13.40% 2010/5312 |
- - |
- - |
| 2025 | 32.94% 1142/4813 |
3.57% 1068/3635 |
2.67% 1437/4076 |
21.58% 1763/4524 |
2.83% 833/4813 |
| 2024 | 8.82% 1513/3463 |
-0.60% 1130/2808 |
-4.44% 1508/3014 |
13.80% 2103/3129 |
0.68% 1182/3463 |
| 2023 | -5.99% 800/2656 |
5.93% 741/2280 |
-3.35% 779/2385 |
-4.61% 1182/2515 |
-3.74% 776/2655 |
| 2022 | -17.67% 617/2207 |
-11.25% 492/1919 |
3.17% 1200/2016 |
-11.26% 519/2113 |
1.32% 1306/2208 |
| 2021 | 14.90% 318/1822 |
3.37% 181/1255 |
9.66% 539/1330 |
1.43% 450/1466 |
-0.06% 1192/1822 |
| 2020 | - - |
- - |
- - |
- - |
-1.79% 1115/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 中加中证500指数增强A VS. 长安沪深300非周期A(740101) |